Ajanta Pharma promoter releases pledge on 1.73 million shares

What Ajanta Pharma announced

Ajanta Pharma Ltd (BSE: 532331, NSE: AJANTPHARM) disclosed that its promoter, the Ravi Agrawal Trust, has released a pledge on 1,732,792 equity shares of the company. The release was effected on 25 June 2026 and reported to the stock exchanges on 26 June 2026 under Regulation 31(1) and 31(2) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. The promoter cited excess pledge as the reason for the un‑encumbrance.

Details of the pledge release

The filing lists the promoter’s shareholding and the portion that was pledged prior to the release. As of the reporting date, the Ravi Agrawal Trust held 12,792,904 shares, representing 10.24% of Ajanta Pharma’s total share capital. Of this, 3,430,488 shares (2.75% of the promoter’s holding) were pledged for business financing purposes. The release on 25 June 2026 removed 1,732,792 shares from the pledged pool, reducing the encumbered portion to 1,697,696 shares (1.36% of total capital).

The table in the filing breaks down the release by lender:

• Tata Capital Limited – 498,700 shares (0.40% of total capital)
• Barclays Securities (India) Private Limited – 2,931,788 shares (2.35%)
• Deutsche Investments India Private Limited – 2,754,140 shares (2.20%)
• Infina Finance Private Limited – 795,333 shares (0.64%)
• Aditya Birla Capital Limited – 1,958,807 shares (1.57%)
• Other minor releases – 261,111 shares (0.21%)

These releases collectively sum to the 1,732,792 shares mentioned in the promoter’s letter.

Regulatory framework

The disclosure is made under Regulation 31(1) & 31(2) of SEBI’s SAST Regulations, 2011, which require promoters to inform the exchange and the target company whenever there is a creation, release, or invocation of an encumbrance on shares. The filing includes the standard format prescribed by SEBI, listing the promoter’s total holding, the encumbered portion before and after the event, the type of encumbrance (pledge), and the reason (excess pledge). The filing was digitally signed by Ravi Purushottam Agrawal on 26 June 2026 at 12:44 IST.

Key facts at a glance

Why this matters for investors

The release of pledged shares reduces the promoter’s encumbrance, which can be viewed as a de‑risking step for existing shareholders. A lower pledged percentage means fewer shares are subject to liquidation in case of loan defaults, potentially improving the stability of the promoter’s stake. However, the filing does not indicate any new financing, share buy‑back, or capital‑raising activity. The change is purely an internal restructuring of the promoter’s collateral arrangements.

Investors should note that the promoter still retains a significant equity stake (over 10% of total capital), and the remaining pledged shares (1.36% of total capital) continue to be held as security for business financing. The disclosure satisfies SEBI’s transparency requirements and does not trigger any immediate regulatory action.

Conclusion

Ajanta Pharma’s promoter, the Ravi Agrawal Trust, has formally released a pledge on 1.73 million shares, lowering its encumbered holding from 2.75% to 1.36% of the company’s total share capital. The action, reported on 26 June 2026, complies with SEBI’s SAST regulations and is driven by an excess‑pledge rationale. No further corporate actions were announced, and the promoter’s overall equity position remains unchanged.